GlaxoSmithKline and Adolor reached the Entereg summit. After a four-year climb, the two companies finally got FDA approval to sell the anti-constipation drug Entereg. It's OK'd for use after abdominal surgery, and will be available under a risk-management program designed to prevent long-term outpatient use. The approval was delayed several times when the agency asked for more data, concerned about side effects such as heart problems that might arise with long-term use.
- here's the release on the approval
- see the story in Forbes
- check out the Philadelphia Inquirer article